FDA Watchdog Will Deliver 2014 Shine Lecture on Wednesday
Forbes Magazine dubbed him “The FDA’s Big Bad Wolfe.”
He has battled the introduction of new medications by the pharmaceutical industry so aggressively that a Boston doctor once snapped, “Is there any drug Sid Wolfe likes?”
After 40 years of holding federal regulators and the drug industry accountable, Dr. Sidney Wolfe, who will deliver the 2014 Cathy Shine Lecture at the BU School of Public Health on Wednesday, March 5 at noon, is accustomed to the jabs — and even welcomes them.
He prides the work of his Public Citizen Health Research Group on having pushed the Food and Drug Administration to take more than two-dozen unsafe drugs off the market and on pointing out safety risks in dozens more, including the painkiller Vioxx, which was withdrawn from the market in 2004, and the diabetes drug Avandia, which saw sales plunge after a black-box label warning about heart risks was imposed. Wolfe’s group got a warning against Reye’s syndrome put on the side of aspirin bottles, and got silicone breast implants restricted.
Just last week, the Health Research Group petitioned the FDA to immediately add a black-box warning about the increased risks of heart attacks and other dangers to the labels of all testosterone-containing drugs sold in the U.S., after a recent study found a significantly increased risk of heart attack in men who took the drugs.
“Considering how many drugs have been approved in 40 years, we’ve really only questioned a handful,” said Wolfe, the longtime director, and now senior advisor, for the health research group he co-founded with consumer activist Ralph Nader in 1971. “We only step in when there are clear safety concerns that are being overlooked — and when the drug in question has no advantage over other drugs already on the market.”
Of the “Big Bad Wolfe” moniker, he laughed: “I think that’s probably disparaging to wolves.”
Wolfe, author of the book, “Worst Pills, Best Pills,” will speak about the failings of regulatory agencies, including the FDA, to ensure that patients are properly protected against risk and harm. The Public Citizen Health Research Group also monitors state oversight of physicians who practice substandard medicine, among many other issues related to patient safety.
Wolfe has published extensively in medical and health policy journals and now writes a regular column for the British Medical Journal. He served on the FDA Drug Safety and Risk Management Advisory Committee from 2008 to 2012. His awards include a 1990 MacArthur Foundation Fellowship.
In advance of his talk, Wolfe discussed his work and views on the status of regulatory oversight:
You’ve been battling the FDA for four decades to get certain drugs off the market or to acknowledge problems with drugs or devices. Are we any better off now than when you started out, in terms of the FDA review process?
“The leadership of the FDA is almost as bad as it has ever been, especially for drugs. Combined with the major funder of drug review no longer being the U.S. taxpayer — but, instead, direct cash from drug companies to the FDA, via the 1992 Prescription Drug User Fee Act — the situation is miserable. However, during these 40-plus years, we have been able to force open more information from the FDA and to push the agency to ban more than two-dozen prescription drugs.”
Why aren’t safety concerns – such as the painkiller Darvon’s potential impact on the heart, which you pushed for decades – picked up during the FDA review process?
“The power of a study to find safety risks is a function of how big the study is. The FDA requires drug companies to show that a drug works – i.e., a drug for diabetes just has to lower your blood sugar. If it causes increased heart failure or heart attack — that may not show up in a smaller study. There’s a split between the smaller numbers of people you need to show that a drug’s effective vs. the larger numbers to assess whether it’s safe. The standard for safety is greatly hampered by the fact that you don’t have enough people enrolled to really answer important safety questions – so you have drugs prematurely thrown on the whole population in what I would call an experimental way.
“Combined with an increasingly faster review process, this is too frequently a recipe for disaster.”
Doesn’t the FDA advisory committee serve as a check against potentially dangerous drugs coming on the market?
“It should, but it doesn’t. Even when there are safety concerns, the FDA often sides with the drug makers. There are cases where the FDA advisory committee says, ‘this drug is too dangerous,’ and the FDA approves it anyway.
“Before the weight-loss drug Meridia was approved in 1997, the primary FDA physician who reviewed it said it was too dangerous – it caused increased blood pressure and pulse in some patients—and should not be approved. The advisory committee voted not to approve it, but the FDA was eager to approve another weight loss drug because it had just taken one off the market. In 2002, we petitioned to have it removed, but the FDA rejected our petition. After a subsequent European study showed a large increase in strokes and heart attacks, it was immediately banned in Europe — but not here until later, after we had petitioned again. What the European study found was predictable before approval.
“Too often, the FDA has its mind made up in advance. And overall, only about a third of drugs even have to go through an advisory committee.”
You’ve watched Big Pharma up close and once said that there’s a “pathological lack of corporate integrity” in many drug companies. Do you see that changing, after all the litigation against drug companies in the last decade, and the new transparency rules under Obamacare?
“Criminal and civil penalties against Big Pharma have escalated enormously in the past several years, but their size is outstripped by the financial gains from these illegal activities. Thus, we consider such behavior to literally be part of their business model.
“The transparency, if it is ever finalized and put into practice, will disclose the extent to which individual doctors are on the take of Big Pharma (receiving payments as speakers and consultants). But those who are not embarrass-able will continue to benefit from Big Pharma largesse.”
Public Citizen has done a lot of work to shine a light on the lack of discipline of physicians by state medical boards. Why do you think so many of these boards are ineffective?
“For more than 20 years, we have ranked state medical boards on the basis of their rates of serious disciplinary actions against doctors. As in the case of the FDA — but, in this case varying by state — inadequate, ineffective oversight of important disciplinary decisions explains much of the discrepancies between states.
“There’s a case in Texas where a neurosurgeon on the staff of a hospital botched procedures in which patients were injured or died, and instead of taking any action against him, the hospital wrote him a de facto letter of recommendation. He went on to another hospital, where he caused further harm. Almost half of the hospitals in the country have never reported taking action against even one doctor – not one — in 23 years.
“In addition to shortcomings at most medical boards and hospitals, inactivity by the appropriate state legislators, and the spotty role of the press in illustrating the downsides to patients of an underperforming board, need to be remedied.”
Do you see any initiatives on the horizon – ‘medical homes’ or bundled payments to doctors – that will help to reduce medical errors and overprescribing?
“I agree with (former New England Journal of Medicine editor) Bud Relman and many others that unless we go to a single-payer, improved Medicare-for-all system — combined with salaried doctors, eliminating for-profit considerations from ordering tests, and the rampant Big Pharma doctor-bribing that rewards overprescribing — these goals cannot be accomplished. Better medical education about the dangers to patients of over-testing and overprescribing would help. In addition, effective institution-based quality improvements and more effective medical board actions could help to reduce errors.”
What’s available to consumers who want to check out their drugs?
You can find information on drugs on our website, Worst Pills.org. There’s also more information out there on the Internet because of lawsuits we filed against the FDA to get some of their documents out into the public. Whenever there’s an FDA advisory committee meeting they now have to post the documents on their website at least 48 hours in advance to allow public participation. We also pushed the FDA to make information available sooner after a drug is approved. It’s better than it was, in terms of getting information out there.
The Shine lecture is noon to 1 p.m. Wednesday in the Hiebert Lounge, 14th Floor, 72 East Concord St., on the BU Medical Campus. The event, sponsored by the BUSPH Department of Health Law, Bioethics & Human Rights, is free and open to the public.
Submitted by: Lisa Chedekel